FDA Lab Testing Confirms SAB Biotherapeutics' COVID-19 Antibody Neutralizes Omicron Variant

SAB Biotherapeutics Inc SABS announced that SAB-185, its COVID-19 therapeutic candidate, retains neutralization activity against the omicron variant in an in vitro pseudovirus model. 

  • The results indicate that SAB-185 retains a potent ability to neutralize recombinant S protein lentiviral pseudovirus that mimics the SARS-CoV-2 Omicron (B.1.1.529) variant. 
  • Although SAB-185 retained potent neutralization of the omicron variant, it did show a mild-moderate reduction in potency compared to the wild type. 
  • Additional analyses are ongoing, and the full data set is being prepared for bioRxiv, the online life sciences archive for COVID-19 SARS-CoV-2 preprints.
  • SAB-185 is currently being assessed in a Phase 3 trial compared to active control monoclonal antibody treatment in people with mild to moderate COVID-19 who are at higher risk for progression to hospitalization. 
  • It is enrolling approximately 600 participants to receive SAB-185 and 600 to receive an active comparator. 
  • The primary outcome measures include safety and non-inferiority to prevent a composite endpoint of either hospitalization or death from any cause through study day 28.
  • Price Action: SAB Biotherapeutics' Influenza Candidate Achieves Primary Goal In Mid-Stage Study.
  • Price Action: SABS shares are up 3.59% at $10.10 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Coronaviruswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!